#ASCO21 Press Release: JUPITER-02 Trial- Toripalimab plus standard first-line chemo significantly delayed disease progression for pts w recurrent or metastatic nasopharyngeal carcinoma fal.cn/3fQ5G #hncsm #immunoonc

According to data from a landmark phase 3 trial, in the ITT population of patients with advanced primary SCCHN, the Multikine treatment regimen yielded an OS benefit of 14.1%. #hncsm ow.ly/HoEg50FlLAw

Cabozantinib demonstrates efficacy in radioactive-iodine and VEGFR refractory patients. Another option for thyroid cancer patients but keep in mind the importance of molecular testing to find actionable alterations in NTRK, RET, and BRAF. thelancet.com/journals/lanon…

In the phase III JUPITER-02 trial, addition of the anti-PD-1 antibody toripalimab to first-line gemcitabine plus cisplatin for pts with advanced-stage nasopharyngeal carcinoma improved PFS 11.7 vs 8.2 months and also OS (HR 0.61, P = 0.046): nature.com/articles/s4159… #hncsm

It's World Cancer Research Day and Dr. Cesar Perez, Director of Drug Development at Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, is sharing his wisdom on the importance of clinical trials in the life of patients facing cancer. #WorldCancerResearchDay

.U.S. FDA granted a fast track designation to KIN-2787 in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma. Cesar Sarah Cannon Docs #melcsm ow.ly/S58P50LtLgL

Cesar Miriam Mutebi @asco #asco23

Si la montaña no va a Mahoma, Mahoma va a la montaña. ( If the mountain does not come to Mohammed…) Visiting our former Sylvester Comprehensive Cancer Center colleague and friend Cesar in Lake Nona, FL. FCS Foundation

Recommendations for Global Curriculum in #MedicalOncology: result of great collaboration btw @myesmo & ASCO and the full support of JCO Global Oncology & ESMO Open

Dr. Cesar Perez presenting at the educational session on Head and neck cancers at ASCO 2024 #ASCO24

The FDA has granted FTD to CRB-701, a next-generation ADC targeting nectin-4, for patients with recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy and an anti-PD(L)1 therapy. hubs.li/Q03JRtl90 #hncsm #oncology #cancer